Hepatic sulfotransferase as a nephropreventing target by suppression of the uremic toxin indoxyl sulfate accumulation in ischemic acute kidney injury

Toxicological Sciences

Volumn 141, Issue 1, 2014, Pages 206-217

  Saito, Hideyuki ^a,b   Yoshimura, Misato ^b   Saigo, Chika ^b   Komori, Megumi ^b   Nomura, Yui ^b   Yamamoto, Yuko ^b   Sagata, Masataka ^b   Wakida, Ayaka ^b   Chuman, Erina ^b   Nishi, Kazuhiko ^a   Jono, Hirofumi ^a,b  

^a KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Acute kidney injury; Indoxyl sulfate; Nrf2; Phytochemical polyphenols; Sulfotransferase

Indexed keywords

AST 120; INDICAN; KIDNEY INJURY MOLECULE 1; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; QUERCETIN; RESVERATROL; TRANSCRIPTION FACTOR NRF2; CARBON; ENZYME INHIBITOR; ISOTHIOCYANIC ACID DERIVATIVE; NFE2L2 PROTEIN, HUMAN; OXIDE; STILBENE DERIVATIVE; SULFORAFAN; SULFOTRANSFERASE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASOLATERAL MEMBRANE; CONTROLLED STUDY; DOWN REGULATION; DRUG ABSORPTION; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; KIDNEY DYSFUNCTION; KIDNEY PROXIMAL TUBULE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; REPERFUSION INJURY; URINARY EXCRETION; ACUTE KIDNEY INJURY; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CELL LINE; DRUG EFFECTS; ENZYMOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPID PEROXIDATION; LIVER; MALE; METABOLISM; SPRAGUE DAWLEY RAT; URINE; WESTERN BLOTTING;

ACUTE KIDNEY INJURY; ANIMALS; BLOTTING, WESTERN; CARBON; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME INHIBITORS; HUMANS; INDICAN; ISOTHIOCYANATES; LIPID PEROXIDATION; LIVER; MALE; NF-E2-RELATED FACTOR 2; OXIDES; QUERCETIN; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; STILBENES; SULFOTRANSFERASES;

EID: 84913619924     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfu119     Document Type: Article

References (46)

1. Adelibieke, Y., Shimizu, H., Muteliefu, G., Bolati, D., Niwa, T. (2012). Indoxyl sulfate induces endothelial cell senescence by increasing reactive oxygen species production and p53 activity. J. Ren. Nutr. 22, 86-89.
2. Ara, C., Karabulut, A. B., Kirimlioglu, H., Coban, S., Ugras, M., Kirimliglu, V., Yilmaz, S. (2005). Protective effect of resveratrol against renal oxidative stress in cholestasis. Ren. Fail. 27, 435-440.
3. Banoglu, E., King, R. S. (2002). Sulfation of indoxyl by human and rat aryl (phenol) sulfotransferases to form indoxyl sulfate. Eur. J. Drug Metab. Pharmacokinet. 27, 135-140.
4. Banoglu, E., Jha, G. G., King, R. S. (2001). Hepatic microsomal metabolism of indole to indoxyl, a precursor of indoxyl sulfate. Eur. J. Drug Metab. Pharmacokinet. 26, 235-240.
5. Belayev, L. Y., Palevsky, P. M. (2013). The link between acute kidney injury and chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 23, 149-154.
6. Bonventre, J. V., Yang, L. (2010). Kidney injury molecule-1. Curr. Opin. Crit. Care 16, 556-561.
7. Chiang, C. K., Tanaka, T., Nangaku, M. (2012). Dysregulated oxygen metabolism of the kidney by uremic toxins: Review. J. Ren. Nutr. 22, 77-80.
8. Dou, L., Jourde-Chiche, N., Faure, V., Cerini, C., Berland, Y., Dignat-George, and Brunet, P. F. (2007). The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J. Thromb. Haemost. 5, 1302-1328.
9. Enomoto, A., Takeda, M., Tojo, A., Sekine, T., Cha, S. H., Kham dang, S., Takayama, F., Aoyama, I., Nakamura, S., Endou, H., Niwa, T. (2002). Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J. Am. Soc. Nephrol. 13, 1711-1720.
10. Enomoto, A., Takeda, M., Taki, K., Takayama, F., Noshiro, R., Niwa, T., Endou, H. (2003). Interactions of human organic anion as well as cation transporterswith indoxyl sulfate. Eur. J. Pharmacol. 466, 13-20.
11. Fujii, H., Nakai, K., Fukagawa, M. (2011). Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease. Ther. Apher. Dial. 15, 125-128.
12. Gelasco, A. K., Raymond, J. R. (2006). Indoxyl sulfate induces complex redox alterations in mesangial cells. Am. J. Physiol. Renal Physiol. 290, F1551-F1558.
13. Goto, S., Kitamura, K., Kono, K., Nakai, K., Fujii, H., Nishi, S. (2013). Association between AST-120 and abdominal aortic calcification in predialysis patients with chronic kidney disease. Clin. Exp. Nephrol. 17, 365-371.
14. Guerrero-Beltr-an, C. E., Calder-on-Oliver, M., Tapia, E., Medina-Campos, O. N., S-anchez-Gonz-alez, D. J., Mart-inez-Mart-inez, C. M., Ortiz-Vega, K. M., Franco, M., Pedraza-Chaverri, J. (2010). Sulforaphane protects against cisplatin-induced nephrotoxicity. Toxicol. Lett. 192, 278-285.
15. Iwata, K., Watanabe, H., Morisaki, T., Matsuzaki, T., Ohmura, T., Hamada, A., Saito, H. (2007). Involvement of indoxyl sulfate in renal and central nervous system toxicities during cisplatin-induced acute renal failure. Pharm. Res. 24, 662-671.
16. Kaushal, G. P., Shah, S. V. (2014). Challenges and advances in the treatment of AKI. J. Am. Soc. Nephrol. 25, 877-883. Kumar, A., Singh, C. K., Lavoie, H. A., Dipette, D. J., Singh, U. S. (2011). Resveratrol restores Nrf2 level and prevents ethanolinduced toxic effects in the cerebellum of a rodent model of fetal alcohol spectrum disorders. Mol. Pharmacol. 80, 446-457.
17. Kumar, A., Singh, C. K., Lavoie, H. A., Dipette, D. J., Singh, U. S. (2011). Resveratrol restores Nrf2 level and prevents ethanolinduced toxic effects in the cerebellum of a rodent model of fetal alcohol spectrum disorders. Mol. Pharmacol. 80, 446-457
18. Kusumoto, M., Kamobayashi, H., Sato, D., Komori, M., Yoshimura, M., Hamada, A., Saito, H. (2011). Alleviation of cisplatin-induced acute kidney injury using phytochemical polyphenols is accompanied by reduced accumulation of indoxyl sulfate in rats. Clin. Exp. Nephrol. 15, 820-830.
19. Lekawanvijit, S., Kompa, A. R., Wang, B. H., Kelly, D. J., Krum, H. (2012a). Cardiorenal syndrome: The emerging role of protein-bound uremic toxins. Circ. Res. 111, 1470-1483.
20. Lekawanvijit, S., Kompa, A. R., Manabe, M., Wang, B. H., Langham, R. G., Nishijima, F., Kelly, D,J., Krum, H. (2012b). Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. PLoS One 7, e41281.
21. Matsuzaki, T., Watanabe, H., Yoshitome, K., Morisaki, T., Hamada, A., Nonoguchi, H., Kohda, Y., Tomita, K., Inui, K., Saito, H. (2007). Downregulation of organic anion transporters in rat kidney under ischemia/reperfusion-induced acute renal failure. Kidney Int. 71, 539-547.
22. Miyazaki, T., Ise, M., Hirata, M., Endo, K., Ito, Y., Seo, H., Niwa, T. (1997). Indoxyl sulfate stimulates renal synthesis of transforming growth factor-beta 1 and progression of renal failure. Kidney Int. 63, S211-S214.
23. Morisaki, T., Matsuzaki, T., Yokoo, K., Kusumoto, M., Iwata, K., Hamada, A., Saito, H. (2008). Regulation of renal organic ion transporters in cisplatin-induced acute kidney injury and uremia in rats. Pharm. Res. 25, 2526-2533.
24. Neirynck, N., Vanholder, R., Schepers, E., Eloot, S., Pletinck, A., Glorieux, G. (2013). An update on uremic toxins. Int. Urol. Nephrol. 45, 139-150.
25. Nii-Kono, T., Iwasaki, Y., Uchida, M., Fujieda, A., Hosokawa, A., Motojima, M., Yamato, H., Kurokawa, K., Fukagawa, M. (2007). Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int. 71, 738-743.
26. Niwa, T. (2010). Indoxyl sulfate is a nephro-vascular toxin. J. Ren. Nutr. 20, S2-S6.
27. Niwa, T. (2011). Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: Experimental and clinical effects of oral sorbent AST-120. Ther. Apher. Dial. 15, 120-124.
28. Niwa, T. (2013). Removal of protein-bound uraemic toxins by haemodialysis. Blood Purif. 35, 20-25.
29. Niwa, T., Ise, M. (1994). Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J. Lab. Clin. Med. 124, 96-104.
30. Niwa, T., Shimizu, H. (2012). Indoxyl sulfate induces nephrovascular senescence. J. Ren. Nutr. 22, 102-106.
31. Owada, S., Goto, S., Bannai, K., Hayashi, H., Nishijima, F., Niwa, T. (2008). Indoxyl sulfate reduces superoxide scavenging activity in the kidneys of normal and uremic rats. Am. J. Nephrol. 28, 446-454.
32. Palsamy, P., Subramanian, S. (2011). Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochim. Biophys. Acta 1812, 719-731.
33. Saito, H. (2010). Pathophysiological regulation of renal SLC22A organic ion transporters in acute kidney injury: Pharmacological and toxicological implications. Pharmacol. Ther. 125, 79-91.
34. Saito, H. (2013). Toxico-pharmacological perspective of the Nrf2-Keap1 defense system against oxidative stress in kidney diseases. Biochem. Pharmacol. 85, 865-872.
35. Shneider, R., Sauvant, C., Betz, B., Otremba, M., Fischer, D., Holzinger, H., Wanner, C., Galle, J., Gekle, M. (2007). Downregulation of organic anion transporters OAT1 and OAT3 correlates with impaired secretion of paraaminohippurate after ischemic acute renal failure in rats. Am. J. Physiol. Renal Physiol. 292, F1599-F1605.
36. Shneider, R., Meusel, M., Renke, S., Baue, C., Holzinger, H., Roeder, M., Wanner, C., Gekle, M., Sauvant, C. (2009). Low-dose indomethacin after ischemic acute kidney injury prevents downregulation of Oat1/3 and improves renal outcome. Am. J. Physiol. Renal Physiol. 297, F1614-F1621.
37. Schulman, G., Agarwal, R., Acharya, M., Berl, T., Blumenthal, S., Kopyt, N. (2006). A multicenter, randomized, doubleblind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am. J. Kidney Dis. 47, 565-577.
38. B, p53, ERK, and JNK in proximal tubular cells. Life Sci. 90, 525-530.
39. B and p53 in proximal tubular cells. Life Sci. 92, 143-148.
40. Thadhani, R., Pascual, M., Bonventre, J. V. (1996). Acute renal failure. N. Engl. J. Med. 334, 1448-1460.
41. Ueda, H., Shibahara, N., Takagi, S., Inoue, T., Katsuoka, Y. (2008). AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren. Fail. 30, 856-860.
42. Vanholder, R., De Smet, R., Glorieux, G., Argil-es, A., Baurmeister, U., Clark, W., Cohen, G., De Deyn, P. P., Deppisch, R., et al. (2003). Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int. 63, 1934-1943.
43. Wu, Q. Q., Wang, Y., Senitko, M., Meyer, C., Wigley, W. C., Ferguson, D. A., Grossman, E., Chen, J., Zhoum, X,J., Hartono, J., et al. (2010). Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1. Am. J. Physiol. Renal Physiol. 300, F1180-F1192.
44. Wu, L., Zhang, Y., Ma, X., Zhang, N., Qin, G. (2012). The effect of resveratrol on FoxO1 expression in kidneys of diabetic nephropathy rats. Mol. Biol. Rep. 39, 9085-9093.
45. Ympa, Y. P., Sakr, Y., Reinhart, K., Vincent, J. L. (2005). Has mortality from acute renal failure decreased? A systematic review of the literature. Am. J. Med. 118, 827-832.
46. Yoon, H. Y., Kang, N. I., Lee, H. K., Jang, K. Y., Park, J.W., Park, B. H. (2008). Sulforaphane protects kidneys against ischemiareperfusion injury through induction of the Nrf2-dependent phase 2 enzyme. Biochem. Pharmacol. 75, 2214-2223.